Atrial Fibrillation (Permanent), Congestive Heart Failure Chronic
Conditions
Keywords
atrial fibrillation, congestive hearth failure, cytokine, miRNA
Brief summary
the goal of this case-control cross-sectional study is assessing in a cohort of patients with CHF and permanent AF * The serum levels of some candidate cytokine variables and their relationship with some selected metabolic variables and some echocardiographic variables. * the expression degree of some selected miRNA with a pathogenetic relation to atrial fibrillation and the related cardiac remodelling. * to analyze the correlation between selected miRNA and the selected cytokines.
Interventions
None listed
Sponsors
University of Palermo
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥18 years * Left ventricular ejection fraction \>40% * New York Heart Association class II-IV symptoms * NT-proBNP ≥600 pg/mL, or ≥900 pg/mL if AF was present on baseline electrocardiography
Exclusion criteria
\- Other AF subtypes (paroxysmal, persistent, long-standing persistent) At least one of the following criteria: * Acute heart failure * NYHA IV * NT-proBNP \>4000 pg/mL * Significant valvular disease * Mechanical prosthesis * Cardiovascular implantable devices * Active malignancy * Inflammatory or infectious diseases * Severe renal (eGFR \<30 mL/min/m²) or hepatic failure * Chronic steroid/anti-inflammatory therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| inflammation and structural cardiac remodelling | From January 2020 to May 2022 | in both arms of the study (AF + CHF and CHF no AF) a blood sample will be performed for the determination of serum values of inflammatory cytokines (CRP in mg/l; IL6 in pg/ml) and a transthoracic echocardiogram for the evaluation of the left atrial volume index in ml/m2 and the left atrial strain % |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| epigenetic alterations and cardiac remodelling | From January 2020 to May 2022 | in both arms of the study (AF + CHF and CHF no AF) a blood sample will be performed for the determination of the expression degree of some selected miRNA with a pathogenetic relation to atrial fibrillation (hsa-miR-1-3p, hsa-miR-26a-5p, hsa-miR-21-5p in nmol/l), and a transthoracic echocardiogram for the evaluation of the left atrial volume index in ml/m2 and the left atrial strain % |
| inflammation and epigenetic alterations | From January 2020 to May 2022 | in both arms of the study (AF + CHF and CHF no AF) a blood sample will be performed for the determination of the expression degree of some selected miRNA with a pathogenetic relation to atrial fibrillation (hsa-miR-1-3p, hsa-miR-26a-5p, hsa-miR-21-5p in nmol/l), and a blood sample for the determination of serum values of inflammatory cytokines (CRP in mg/l; IL6 in pg/ml) |
Countries
Italy
Outcome results
None listed